All In MedTech

FDA Clearance Tracker · P860057-S202

Carpentier-Edwards PERIMOUNT Magna Pericardial Aortic Bioprostheses

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 13, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 13, 2021

Approved

Time to decision

146 days

Received Jul 20, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P860057-S202
Device name
Carpentier-Edwards PERIMOUNT Magna Pericardial Aortic Bioprostheses
Applicant location
Irvine, CA
Received
Jul 20, 2021
Decided
Dec 13, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P860057

Device type

Device class
Class III
Regulation
21 CFR 870.3925

Every decision under product code DYE

FDA's approval statement

As written in FDA's record.

Approval for the manufacturing of the Carpentier-Edwards PERIMOUNT Magna Pericardial Aortic Bioprosthesis (MAGNA Model 3300TFX) at the Edwards Cartago, Costa Rica Facility, limited to cleaning and sterilization of components, bioburden reduction, final assembly, terminal liquid sterilization, and packaging and labeling prior to commercial release.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.